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TLR-mediated stimulation of APC: Distinct cytokine
responses of B cells and dendritic cells
Tom A. Barr, Sheila Brown, Gemma Ryan, Jiexin Zhao and David Gray
Institute of Immunology and Infection Research, School of Biological Science,
University of Edinburgh, Edinburgh, UK
In addition to their role in humoral immunity, B lymphocytes are important antigen-
presenting cells (APC). In the same way as other APC, B cells make cytokines upon
activation and have the potential to modulate T cell responses. In this study, we
investigated which mouse B cell subsets are the most potent cytokine producers, and
examined the role of Toll-like receptors (TLR) in the control of secretion of IL-6, IL-10,
IL-12 and IFN-c by B cells. Production of some cytokines was restricted to particular
subsets. Marginal zone and B1 cells were the predominant source of B cell IL-10 in the
spleen. Conversely, follicular B cells were found to express IFN-c mRNA directly ex vivo.
The nature of the activating stimulus dramatically influenced the cytokine made by
B cells. Thus, in response to combined TLR stimulation, or via phorbol esters, IFN-c was
secreted.IL-10was elicited byT-dependentactivationorstimulationthrough TLR2,4or
9. This pattern of cytokine expression contrasts with that elicited from dendritic cells.
QRT-PCR array data indicate that this may be due to differential expression of TLR
signalling molecules, effectors and adaptors. Our data highlight the potentially unique
nature of immune modulation when B cells act as APC.
Introduction
It is now generally accepted that recognition of foreign
organisms or damaging circumstances by cells of the
innate immune system, i.e. antigen-presenting cells
(APC), triggers immune response initiation. Such
recognition events lead to maturation of these APC to
enable presentation of processed antigen to T cells in
immunogenic form, involving provision of costimula-
tion. Innate cells recognise pathogen-associated mole-
cular patterns (PAMP) [1, 2] or tissue damage [3–5] by
their expression of pattern recognition receptors (PRR).
One of the most important groups of PRR is the Toll-like
receptor(TLR)familyof type Itransmembraneproteins,
characterised by highly divergent, leucine-rich extra-
cellular domains and highly conserved Toll-IL-1R (TIR)
cytoplasmic domains. To date, 12 murine and human
TLR have been described. Humans express TLR1–10 and
13andthemouseexpressesTLR1–9,11and13(TLR11is
also called TLR12 by Tabeta et al. [6]). The ligands for
TLR1–9 and 11 have now been described [7–10]. TLR
are linked via adapter molecules to intracellular
signalling pathways that generally lead to transcription
of NF-jB target genes. Among these targets are cytokine
genes, and it is these that are crucial not only for the
initiation of the adaptive response but also in shaping its
direction. For example, in the absence of the major TLR
adapter, MyD88, there is little IL-12 production and a
failure of the Th1 response [11]. In relation to this
process, most attention has centred on dendritic cells
(DC) as the main initiating APC. However, B cells are no
different from other APC in their need for maturation
signals to allow them to attain their full presentation
capacity. Furthermore, it is now being revealed that TLR
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production in normal and autoimmune responses
[12–17]. To date, there has been no systematic study
of TLR expression by B cells and how they respond to
various TLR signals.
B cells do not participate significantly as initiators of
the immune response, either because they cannot
activate naive T cells [18] or because the frequency of
antigen-specific B cells, the only efficient B cell
presenters, is far too low. However, they do become
important APC later in the primary response and in the
secondary one, where their increased numbers means
they may be the predominant antigen-presenting force
[19]. We and others have demonstrated an important
contribution of B cells as activators of Tcells in vivo[20],
a contribution that is both early (clonal expansion and
Th differentiation; [21, 22]) and late (immune regula-
tion; [22–24]) and is delivered bysecretion of cytokines,
in particular IL-10 [23, 25, 26]. The B cell compartment
comprises several subsets, and it is becoming apparent
that not all are equal in their capacity to present antigen
to T cells; thus, Attanavich et al. [27] report that
marginal zone (MZ) B cells are much more active in this
respect than follicular (FO) B cells. As well as the MZ
versus FO B cell dichotomy (identified by CD21/CD23
expression), the B cell compartment is split into B1 and
B2 populations. MZ and FO B cells are B2 B cells. B1
B cells largely express the marker CD5 and are found in
the peritoneal cavity, and also the spleen. B1 cells
respond to T-independent antigens and are responsible
for the production of most background serum Ig (mostly
IgM); they do not participate significantly in T-depen-
dent responses [28]. B1 and B2 cells seem to arise as
separate lineages [29, 30], although the developmental
relationship between B1 cells and MZ B cells is still not
clear [31].
Published reports suggest that B cells acting as APC
during the primary response lead to a Th2-biased
response [22, 32], in contrast to DC, which often, as a
result of IL-12 production, drive a Th1 response [33]. A
full functional, molecular explanation for this distinc-
tion has yet to be provided. The maturation of DC into
effector DC [34] which have the ability to differentially
drive Th responses is influenced by TLR ligation
[35–37]. As a parallel, it is likely that TLR ligation on
Bcellsinfluencestheir roleasAPC,andindirectingTcell
differentiation. We have looked to see if the contrasting
roles of B cells and DC as APC can be explained by
differences in their expression of TLR or their reactivity
toTLR ligands. We find that while mouse B cells express
mRNA for all TLR, their response to the triggering of
these receptors was clearly distinct.
Results
B cell subsets show differential ex vivo expression
of IL-6, IL-10 and IFN-c mRNA
B lymphocytes isolated from non-immunized C57/BL6
mice by CD19
+ve MACS sorting were found to express
mRNA for IL-10 and IFN-c as determined by reverse
transcription (RT)-PCR (see Fig.1A). Wealsoperformed
RT-PCR reactions on B cell mRNA for the detection of
IL-4 and IL-5, but no message for these cytokines was
detected (data notshown). IL-10 and IFN-c mRNA could
not be attributed to contaminating non-B cells in
preparations, as no message for CD3n could be detected,
indicating an absence of NK and/or Tcells (see Fig.1A).
Additionally, only trace contaminants of CD3
+ve and
CD11c
+ve cells were detected in sorts (0.16 and 0.076%,
respectively – data not shown). CD5
+ve B1 cells from the
peritoneal cavity are known to produce IL-10 [38]. To
investigate cytokine production bysplenic B cell subsets,
we separated purified CD19
+ve B cells into B1/B2 cells
and MZ/FO subsets by FACS. Fig. 1B illustrates high-
purity B cell subset sorts. mRNA was extracted from
thesesamplesand assayed byRT-PCR for thepresence of
IL-6, IL-10, IL-12p40 and IFN-c. As expected, splenic B1
cells expressed IL-10 mRNA, but notmRNA for IFN-c.B 2
cells did not express IL-10 but did express IFN-c mRNA.
This dichotomy was also observed in MZ and FO B cells,
in which MZ B cells from non-immunized animals
expressed IL-10 mRNA but not IFN-c message, while FO
B cells expressed IFN-c but not IL-10 mRNA. IL-12p40
mRNA was not detected in the CD19
+ve B cell prepara-
tionor inanyof theenrichedBcellsubsetsorts(Fig.1A).
The lack of detectable IL-10 message in the B2 mRNA
was unexpected, as this sort would presumably contain
some MZ cells. It seems likely that the number of MZ
cells present in the B2 sort was below the detection limit
of the IL-10 PCR. The B cell subset cytokine dichotomy
was quantified by quantitative real-time reverse tran-
scription (QRT)-PCR analysis of IL-10 and IFN-c mRNA
in B1/B2 MZ/FO subsets (Fig.1C). FO and B2 cells were
found to express high levels of IFN-c mRNA but
negligible levels of IL-10. B1 cells expressed the highest
levels of IL-10 mRNA, followed by MZ cells. These
subsets expressed negligible levels of IFN-c mRNA
(Fig. 1C). The differences in IFN-c and IL-10 gene
transcript levels point to the potential for B cell subsets
toproduce differentcytokinesbasedontheir phenotype.
Murine B cells express TLR1–9
Given the importance of TLR in driving APC maturation,
we sought to quantify TLR transcript levels of B cell
subsets. mRNA from purified CD19
+ve splenic B cells
was extracted and analysed by RT-PCR to investigate the
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+veB cells were found
to express mRNA for all of the nine TLR tested in this
investigation (see Fig. 2A).
MZ and B1 cells express a different TLR repertoire
to FO and B2 cells
QRT-PCR analysis of mRNA extracted from B cell subsets
confirmed the previous observation that B cells express
mRNA for all nine TLR in all subsets tested (Fig. 2B).
TLR1, 2, 4, 7 and TLR9 transcripts were high amongst
B cells, while comparatively TLR3, 5, 6 and 8 showed
low expression. Levels of TLR mRNA differed between
B cell subsets. B1 and MZ B cells displayed TLR mRNA
expression levels distinct from B2 and FO cells. B1 and
MZ cells expressed higher levels of TLR2, 6 and 7
transcripts than their B2 and FO counterparts. These
subsets also expressed lower levels of TLR8 mRNA than
B2 and FO cells (Fig. 2B).
Activation of B cells via TLR
Activation and subsequent up-regulation of costimula-
tory molecules by B cells in response toTLR stimulation
in vitro was measured by flow cytometry following
overnight stimulation (Fig. 3A). LPS (TLR4) and
PAM3CSK4 (TLR2) both up-regulated CD40 expression.
These two agonists were alsothe only stimuli to induce a
substantial increase in CD23 expression, although a
small increase was apparent in CpG-treated B cells.
CD25 expression was substantially enhanced by
PAM3CSK4 and LPS treatment and to a lesser extent
by loxoribine, flagellin and CpG. MHC class II expres-
sion was augmented by all of the TLR agonists tested,
excluding zymosan and the negative control non-CpG
oligonucleotide. CD80 expression levels were slightly
increased in B cells stimulated through TLR2, 4, 7 and 9.
CD86 expression was strongly up-regulated through
stimulation via TLR2, but only with PAM3CSK4 and not
Figure 1.CytokinemRNAexpressionby B cells.B cellswerepurifiedby CD19
+ve MACS, thenFACSsortedaccordingtoexpressionof
cell surface markers. (A) RT-PCR analysis of mRNA extracted from cell sorts; +ve is the positive control (unsorted splenocytes).
Semi-quantitative RT-PCR for b-actin, IL-6, IL-10, IL-12p40 and CD3n are shown. (B) Flow cytometry-based sorting of B cell subsets
on CD19
+ve pre-sorted splenocytes. Upper panels show MZ/FO sorting based on expression of CD21 and CD23. Lower panels show
B1/B2 cell sorting based on expression of CD5 and B220. (C) QRT-PCR analysis of mRNA from MZ/FO and B1/B2 cell sorts. cDNA
concentrations,relativeto theb-actinhousekeepingcontrol gene, areindicated for IFN-candIL-10.Error barsindicateSEMonPCR
performed on two separate RNA samples, each extracted from pooled cells from five mice.
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stimulation. B cells were cultured overnight
with a range of TLR agonists as indicated at
the top of the graph. Cellswere then stained
withmAbagainsta rangeofB cellactivation
markers, as indicated on the left. For each
plot, the mean fluorescent intensity is
plotted against % of maximum, with the
filled grey histogram representing staining
for unactivated B cells (incubated overnight
in the absence of any TLR stimulus) and the
open histogram representing staining of
cells activated in the presence of the
corresponding TLR agonist. (A) Splenic
CD19
+ve B cells. (B) MZ B cells (CD19
+ve,
B220
+ve, CD21
high, CD23
int/low). (C) FO B cells
(CD19
+ve, B220
+ve, CD21
+ve, CD23
high). Re-
presentative data from three separate ex-
periments are shown.
Figure 2. B cell expression of TLR mRNA. (A) RT-PCR performed on mRNA extracted from highly purified CD19
+ B unsorted
splenocytes(+ve)andnegativecontrol(H2O).(B) DifferentialexpressionofTLRmRNAbyMZ,FO,B1andB2Bcellsubsets.Allvalues
aregivenasDNAconcentrationsrelativetotheexpressionlevelsoftheb-actinhousekeepinggene.Resultsshownarebasedonthe
mean values calculated from two separate reactions performed on pooled cells from five mice per group.
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following stimulation through TLR3, 4, 5, 7and 9. Again
non-CpG oligonucleotide (TLR negative control) did not
induce up-regulation of this costimulatory molecule.
FACS-sorted MZ and FO subsets were also incubated
overnight with each of the TLR ligands and assayed for
up-regulation of CD25 and CD86 (see Fig. 3B, C). CD25
was up-regulated on MZ cells by stimulation through
TLR2,7,9andtoalesser extent throughTLR4. Similarly,
MZ expression of CD86 was increased by TLR2, 4, 7 and
9 stimulation. FO B cell activation followed a similar
pattern to that displayed by whole CD19 B cells and MZ
cells; however, their propensity for activation was
generally lower (see Fig. 3B). TLR2- and 9-stimulated
FO cells showed elevated CD25 and CD86. A small up-
regulation of these activation markers was also seen
with TLR3, 4 and 7.
Figure 4. Cytokine production by DC and B cells stimulated with TLR agonists. Highly purified B cells and DC were cultured at
2   10
6 cells/mLinthepresenceofarangeofstimuli,eitheralone(whitebars),orinthepresenceofanti-CD40antibody(greybars).
After 5 days, culture supernatants were harvested and assayed by ELISA to determine the concentrations of IL-6, IL-10, IL-12p40
and IFN-c. Data shown are based upon triplicate cultures of pooled cells sorted from four mice and are representative of four
separate experiments. Error bars represent SEM. The limits of detection for each ELISA were as follows: IL-6 = 0.3 ng/mL; IL-10 =
0.1 ng/mL; IL-12p40 = 0.1 ng/mL; and IFN-c = 0.8 ng/mL.
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patterns from B cells and DC
CD19
+ve B cells and CD11c
+ve bone marrow-derived DC
(BMDC) were cultured with agonists for TLR2, 3, 4, 5, 7
and 9. After 5 days, supernatant was collected to
quantify cytokine levels. Time course experiments to
quantify cytokine levels at days 1, 3 and 5 were
performed, of which day 5 was found to be the peak
of cumulative cytokine production (data not shown).
B cells and DC responded very differently to TLR
stimulation with respect to their cytokine secretion
(Fig. 4). CpG (TLR9), LPS (TLR4) and peptidoglycan
(PGN –TLR2)werefound tobethemostpotentinducers
of B cell-derived IL-6, being especially effective in
conjunction with CD40 stimulation. Low levels of IL-6
were also elicited from B cells treated with PAM3CSK4,
PGN (TLR2) and LPS (TLR4). In contrast, DC secreted
IL-6 levels some tenfold higher than those seen in B cells
with PGN (TLR2), LPS (TLR4) and CpG (TLR9).
Additionally, DC responded to poly I:C (TLR3 in
conjunction with CD40 stimulation) and to a lesser
extent to CD40 stimulation alone.
B cells activated in a T-dependent fashion, via
simultaneous ligation of the BCR and CD40, are known
to make IL-10, and this observation was confirmed by
our data (Fig. 4). Additionally, we found that B cells
stimulated with PAM3CSK4 (TLR2), PGN (TLR2), LPS
(TLR4) or CpG (TLR9) also secreted IL-10. Costimula-
tion with anti-CD40 antibody led to a small increase in
IL-10 production through TLR2 and 4, but not with
TLR9. This contrasts with the DC response to TLR
stimulation, where production of IL-10 was strongly
induced byzymosantreatment(TLR2/dectin-1), butnot
with PAM3CSK4 or PGN (TLR2). IL-10 was also elicited
from DC treated with LPS. As with B cells, CD40
stimulation of DC synergised with the TLR stimulus to
enhance IL-10 production.
IL-12p40 secretion was strongly induced in DC
treated with all of the TLR agonists tested, especially
PGN (TLR2), LPS (TLR4), flagellin (TLR5) and CpG
(TLR9). As expected from previous studies [35, 37],
CD40 synergised with TLR stimulation to augment
cytokine secretion. Very lowlevels of IL-12p40 were also
detected in some TLR-treated B cell cultures (loxoribine,
CpG,andtoalesserextentwithzymosanorPAM3CSK4).
It is noteworthy that IL-12p40 levels detected in B cell
cultures were at the threshold of sensitivity for the assay
and were 1000-fold less than IL-12p40 elicited from DC
in the same conditions.
Finally, IFN-c secretion from B cells was not detected
in response to any single TLR or T-dependent stimulus,
only following mitogenic stimulation with PMA and
ionomycin or with discrete combinations of TLR
agonists (see below). IFN-c secretion by BMDC in
responsetoTLR stimulation or with PMA and ionomycin
was also negligible.
ELISAwere alsoperformed for thedetectionof Bcell-
derived IL-4, IL-17 and IL-23. Of these cytokines only
IL-23 was detected, but in response to PMA and
ionomycin and not to any TLR stimulus (data not
shown).
Table1.QRT-PCRanalysisofTLRsignalling-associatedgenesin
DC and B cells
a)
BMDC CD19
+ve B cells
Adaptors
Btk 0.39 4.86
Hspa1a 34.34 0.44
Myd88 0.78 1.21
Tirap 0.38 0.68
Tollip 1.2 0.64
Effectors
Casp8 1.07 1
FADD 0.2 0.99
TRAF6 1 0.61
NF-jB pathway
Ccl2 2.96 0.44
Il-1a 19.11 0.44
NF-jB 1.39 1.16
NF-jB2 1.19 1.16
JNK/p38 pathway
c-Fos 1.78 0.38
Junc 2.05 0.54
Map2K4 0.65 0.95
Elk-1 0.79 0.08
NF/IL-6 pathway
Il-6R 0.08 0.29
IRF-1 2.33 1.11
IRF-3 0.39 0.41
PTGS2 557.18 0.44
Other
Clec4e 30.57 1.69
CXCL10 97.07 7.57
Eif2ak2 1.27 3.43
a) DC or B cells (2   10
6) were incubated for 24 h with LPS.
Following RNA extraction, DNase treatment and cDNA
synthesis QRT-PCR analysis was performed using a TLR-
focused array. Values in the table indicate fold change in
expression level compared with unstimulated cells, where-
by less than 1 indicates down-regulated expression.
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expression profiles in DC and B cells
The observation that B cells and DC display different
cytokine profiles in response to the same TLR stimulus
was intriguing and we sought to identify the mechan-
isms underlying this observation. In order to address
this, we looked at the expression levels of a number of
TLR signalling-associated genes before and after LPS
stimulation using a QRT-PCR-based array system (see
Table 1). Several striking differences were observed
between the transcript expression levels between the
two cell types. In terms of TLR adaptor molecules, DC
greatly up-regulated expression of heat shock
protein 1A (Hspa1a, 34-fold increase) whereas B cells
down-regulated expression (approximately twofold
decrease). In contrast, B cells increased expression of
Bruton's tyrosine kinase (Btk), whereas DC decreased
expression. In terms of the effector molecules Caspase 8
(Casp8), Fas-associated death domain (FADD) and
TNFR-associated factor 6 (TRAF6), only FADD was
differentially expressed with a fivefold decrease in DC
following TLR4 stimulation. Expression of genes in-
volved in the JNK/p38 pathway were more highly
expressed in DC than in B cells. In particular, FBJ
osteosarcoma oncogene (c-Fos) and Jun oncogene
(Junc) showed a small increase in expression in DC,
and Elk-1 showed a large decrease in B cells. The most
striking differences in expression were seen in prosta-
glandin-endoperoxide synthase 2 (Ptgs2), C-type lectin
domain family member 4 (Clec4e) and Cxcl10 expres-
sion, which were all vastly increased in LPS-treated DC,
but only moderately so in B cells.
Defined combinations of TLR agonists cooperate
to elicit IFN-c production from CD19
+ve B cells
It is has been previously demonstrated that defined
combinations of TLR agonists can synergise in their
stimulation of DC to induce increased Th1 polarisation
through the provision of increased levels of IL-12 and
IL-23 [39]. In order to address the potential of TLR
synergyon B cells, we stimulated CD19
+vesplenic Bcells
with combinations of TLR2, 4, 5, 7 and 9 agonists
(Fig. 5). Intriguingly, we found that combined stimula-
tion through TLR2, 4 and 9 (with CpG being particularly
potent) elicits IFN-c production by B cells, a cytokine
previously only produced in response to phorbol esters.
These combinations also led to enhanced IL-10 and IL-6
(see Fig. 5) production from B cells.
TLR stimulation elicits distinct cytokine secretion
patterns from MZ and FO B cells
Highly purified MZ and FO B cell subsets were
stimulated with TLR agonists and combinations that
had previously been demonstrated to elicit IL-10, IL-6
and of IFN-c from whole CD19
+ve B cell stimulations
(Fig. 6). We found that MZ B cells were the main source
of IL-10 from splenic B cell populations; they secreted
IL-10 in response to PAM3CSK4 and PGN (TLR2), LPS
(TLR4) and CpG (TLR9) whereas FO B cells did not.
Additive or synergistic effects were seen with TLR2, 4, 9
Figure 5. Combined TLR stimulation of B cells. CD19 MACS-
purifiedBcellswereculturedwithdefinedcombinationsofTLR
agonists as indicated on the x axis at 2   10
6 cells/mL. After
5d a y so fin vitro stimulation, supernatants were assayed for
levels of IL-6, IL-10 and IFN-c. Data shown are based on
triplicate cultures of pooled cells from groups of four mice and
are representative of four separate experiments. Error bars
indicate SEM. Limits of detection were as follows: IL-6 = 0.3 ng/
mL; IL-10 = 0.1 ng/mL; and IFN-c = 0.8 ng/mL.
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stimulation through all three receptors via LPS,
PAM3CSK4 (or PGN) and CpG. This triple stimulus also
induced a small amount of IL-10 production by the FO
cells, suggesting that, rather than a complete inability to
produce IL-10, the threshold for production from these
cells is significantly higher.
Conversely, the only splenic subset capable of IFN-c
secretion after TLR stimulation were FO B cells. Low
levels were detectable in most FO cultures, but
combined stimulation through TLR2, 4 and 9 or via
mitogenic stimulation via phorbol esters elicited high
levels of production. As with MZ-derived IL-10 produc-
tion, IFN-c elicited from FO B cells was maximal in triple
stimulation through TLR2, 4 and 9. Low levels of IFN-c
could be elicited from MZ B cells, but only with PMA/
ionomycin treatment.
Finally, in contrast to IL-10/IFN-c polarisation, IL-6
did not appear to be preferentially secreted by either
subset. Both MZ and FO B cells secreted IL-6 under
several conditions, including LPS, CpG, PMA/ionomycin
and combinations containing LPS or CpG. However, the
MZ subset provides IL-6 more readily in response to LPS
stimulation. CpG appeared to be a particularly potent
driver of IL-6 production by both subsets of B cells. Both
TLR2 ligands tested (PGN and PAM3CSK4) were
equivalent in their induction of IL-6, IL-10 and IFN-c.
Discussion
The main findings of this study are that mouse B cells
can express all TLR (TLR1–9) and that these function to
activate the cell in avarietyof ways. However, this broad
TLR expression is only true of unseparated (CD19
+ve)
splenic B cells, as subsets of B cells exhibit a differential
TLR expression. Of the TLR ligands tested, only those
binding to TLR2, TLR4 and TLR9 elicited significant
cytokine secretion from B cells (IL-6 and IL-10) when
used alone. However, stimulation through TLR2, 4and 9
in concert elicited IFN-c and enhanced levels of IL-10
and IL-6. When compared to TLR-induced cytokine
secretion by DC, B cells exhibited a distinct pattern,
producing IL-6 and IL-10 in response to TLR4 ligation,
which gave IL-6 and IL-12 in DC. The probable
mechanism underlying divergent cytokine production
in response to TLR stimulation appears to be the
differential use of TLR-associated signalling pathways,
asarray-basedanalysisof thesecell types revealsdistinct
geneprofilesinthetwocelltypesinresponsetothesame
TLR stimulation. Additionally, cytokine production is
also influenced bythetype of respondingB cell; MZcells
produce IL-6 and IL-10 whereas FO B cells secrete IFN-c
and IL-6.
The expression and function of TLR1–9 on mouse
Bcells highlightstheimportance ofPAMPrecognition by
B cells. By analogy with DC, it seems likely that TLR
ligation is an important maturation signal for B cell APC
function. This is demonstrated by the up-regulation of
MHC class II and the costimulation molecules, CD80
and CD86, by all the TLR ligands with the exception of
zymosan. This is also true of the sorted MZ and FO
subsets, although clearly MZ cells showed a higher
propensity for activation. Clearly, the activated pheno-
type is not entirely indicative of cytokine effector
function. For example, the TLR7 ligand, loxoribine,
up-regulates CD25 and CD86 in a similar way to LPS or
CpG, yet despite this, no IL-10 or IFN-c is elicited. Thus,
the activation of the B cell is required but is not
Figure 6. TLR-mediated cytokine production by purified B cell
subsets. B cells isolated by a combination of CD19 MACS
selection and FACS were cultured at 1   10
6 cells/mL with
stimuli known to induce cytokine secretion by whole CD19
+ve
B cells, as indicated on the x axes. After 5 days in culture,
supernatants were harvested and assayed to determine
concentrations of IL-6, IL-10 and IFN-c by ELISA. For each
graph, MZ B cells are represented by white bars and FO B cells
by grey bars. Data presented are based on duplicate cultures of
cells pooled from four mice and representative of four separate
experiments. Error bars represent SEM. Limits of detection
wereas follows:IL-6 =0.3 ng/mL;IL-10= 0.1 ng/mL;andIFN-c=
0.8 ng/mL.
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possible that those TLR ligands inducing activation may
elicit other cytokine responses not covered in this study
(although IL-4, IL-17 and IL-23 were also tested with
negative results; data not shown) or perhaps only act in
a fully stimulatory manner in the presence of other
costimulatory molecules absent in a B cell-only culture.
It is interesting that CD40, a known T-dependent
regulator of costimulatory function of APC, is only
up-regulated on B cells stimulated with TLR2 or TLR4
ligands. This may imply that additional T cell help is
required for optimal responses in these settings, a
hypothesis born out by the observation that cytokine
productionisenhancedwithcostimulationbyanti-CD40
antibody. Not all B cell subsets express all the TLR.
Compared to other subsets, FO and B2 B cells express
less mRNA for TLR2, 6 and 7 and roughly equivalent
amounts of TLR1, 4, 5 and 9 mRNA. Interestingly, MZ
B cells and B1 cells show a clear similarity in TLR
expression, displaying increased levels of TLR2, 6 and 7,
along with decreased levels of TLR8. Both of these B cell
subsets made IL-10 when stimulated with PAM3CSK4 or
PGN, indicating that TLR2 seems functionally active in
this setting. We do not know, at present, the significance
of increasedlevelsof TLR6and7,anddecreasedlevelsof
TLR8. TLR2 and TLR6 are known to form a hetero-
dimeric receptor utilised in the recognition of bacterial
PGN [40], so the similarity in expression levels is not
unexpected. In some subsets mRNA expression was
found to be very low for some certainTLR. Whether this
level of expression is functionally relevant remains to be
determined.
It is striking that not all TLR2 ligands stimulated
B cells; thus, stimulation with PAM3CSK4 or PGN, but
not with zymosan, elicited IL-10 secretion. The likely
reasonforthisisthatBcellsdonotexpressdectin-1[41],
which acts together with TLR2 as a b-glucan receptor
[42]. Lack of dectin-1 expression could provide an
explanation for why B cells cannot respond to zymosan,
while they can respond to PAM3CSK4, as recognition of
the latter is mediated by TLR2 alone. DC, which do
express dectin-1, responded to zymosan by secreting
IL-10. Interestingly, however, they do not do so in
response to PAM3CSK4, indicating that TLR2 itself is
wired differently in B cells and DC. Recently, Syk kinase
has been shown to be necessary for the zymosan-elicited
IL-10 response by DC [43]. However, as Syk was shown
to associate with the cytoplasmic tail of dectin-1, this
again suggests thatthe TLR2-mediated IL-10response in
B cells is elicited via a different signalling pathway. The
cytokine response to PGN is comparable in B cell subset
stimulations (Fig. 6.), indicating that it is indeed the
dectin-1 pathway which is significant in DC. The
response to the other TLR2 ligand, PGN, in this study
is more complicated. As this molecule is isolated from
bacteria, it is often contaminated with LPS. Indeed DC
produce IL-6 in response to PGN, whereas they do not
with PAM3CSK4, which could well indicate an LPS
response (although the lack of IL-10 or IL-12 in these
cultures suggests that any contamination may be at low
levels). Our data illustrate an important distinction
between murine and human B cell TLR repertoires. We
show that murine B cells express TLR1–9, while a recent
study of human tonsillar B cells showed them to express
TLR1, 4, 6, 7, 8, 9 and 10, but not TLR2 [44]. This
contrasts starkly with the results here, in which we show
expression of TLR2 mRNA and show that B cells respond
toTLR2 ligands in avarietyof ways, most importantly by
IL-10 and IL-6 production.
Inorder toinvestigatethedichotomyintheBcelland
DC responses to TLR stimulation, we undertook a QRT-
PCR array-based analysis of TLR-associated signalling
molecules and adaptors. The differences in transcript
levels between B cells and DC in these assays were
striking, with a number of TLR signalling-associated
molecules showing differential expression. For example,
Btkexpression is highly up-regulated in B cells following
TLR4 stimulation, whereas in DC expression is reduced.
Several reports have recently implicated Btk as an
essential molecule in LPS signalling (see [45] for a
review). Much work on Btk has focused on its role as a
regulator of B cell activation, maturation and develop-
ment through BCR-mediated activation; however, the
finding that B cells up-regulate Btk transcription upon
LPS stimulation is intriguing, particularly in light of the
fact that DC do not do likewise. Clearly, this differential
alone is unlikely to account for the differences seen
between B cells and DC in their responses to TLR.
Indeed, from our data, it is clear that a number of
molecules are involved including, but almost certainly
not limited to, Btk, CCL2, FADD, IL-1a, Ptsg2, Clec4e
and CXCL10. Thus, it appears that B cells and DC may
respond by provision of different cytokines to the same
TLR ligand through differential use of intracellular
signalling pathways and their associated adaptor
molecules. It will be intriguing to see how other cell
types and other signalling pathways are exploited in this
way as this is at the core of innate responses; namely,
how pleiotropic events are elicited from conserved
PAMP receptors.
One of the consequences of differential TLR expres-
sion by MZ and FO B cell subsets is a dichotomy in their
ability to make cytokines. Thus, MZ B cells make IL-10
(in response toTLR2 and 4), while FO B cells do not, but
do make IFN-c. The dichotomy is not absolute as with
very strong stimulation (PMA/ionomycin) purified MZ
cells did secrete low levels of IFN-c. Conversely, when
stimulated through TLR2, 4 and 9, FO cells produced a
little IL-10. Both MZ and FO B cells make IL-6, and CpG
stimulation seems an important driver for this response.
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directly ex vivo, following TLR2- and 4-mediated
stimulation and after T-dependent activation (via
CD40). In a similar way to DC [35, 37], we found that
B cells exhibited an additive cytokine response when
exposed to both TLR and CD40 signals. Based on the
data presented, we would predict that in vivo IL-10
production would be optimal only after TLR-activated
B cells interact with CD154-expressing CD4
+ Tcells. As
mentioned already, it is intriguing that the twoTLR that
drive strong IL-10 responses also up-regulate CD40,
which in turn augments the IL-10 response.
B1 cells have been known for over a decade to make
IL-10 [38]. Our finding that MZ cells share the capacity
to produce IL-10 highlights another similarity between
these B cell subsets. The relative IL-10 productivity of B1
cells and MZ B cell populations in vivo is not clear.
Although there are more MZ B cells in the spleen, the
greater capacity of B1 cells to secrete IL-10 suggests that
the two populations contribute similarly to the splenic
IL-10 response.
What function does IL-10 made by these B cells have
in the immune response? IL-10 is a potent inhibitor of
inflammatory responses that exerts part of its effect by
the suppression of IL-12 transcription and secretion by
DC [46]. In a recent study by Sun et al. [47], IL-10
produced by CD5
+ve B cells in response to CpG
stimulation was shown to down-modulate the pro-
inflammatory response of DC. Clearly, the IL-10 elicited
by TLR2 and 4 activation of B cells could be acting in a
similar fashion. Although we stated that splenic B1 and
MZ B cell populations may secrete similar amounts of
IL-10 in vitro, it seems likely that, in vivo, MZ B cells are
better placed to influence DC (and hence T cell)
differentiation, as there are DC within the MZ that
migrate toTcell zones upon TLR4 ligation [48, 49]. The
systemic immunosuppressive role of B cell-derived IL-10
invivohasbeendemonstratedpreviouslybyus[23],and
by other laboratories [25, 50], although whether this
effect is exerted directly on DC or via other cell
populations remains uncertain. An interesting possibi-
lity is that the IL-10 made by B cells is utilised in the
generationof inducible populationsofregulatoryTcells,
some of which (Tr1 cells) are known to be IL-10
dependent in their development [51].
Previous work has shown that CpG acts directly on
B cells, resulting in activation and antibody secretion
[52]. Krieg and colleagues investigated human B cell
responses to TLR stimulation and showed that human
B cells responded via TLR9 to secrete IL-10 and that
there was synergy if the BCR was also ligated [53].
Similarly, Sun et al. [47] have recently shown that
CD5
+ve B cells stimulated with CpG secrete IL-10. Also,
in a mouse model of systemic lupus erythematosus
(SLE), MZ B cells have been shown to respond to CpG by
secretion of IL-10 [54, 55]. Our data agree that MZ
B cells can act as a significant source of IL-10, and that
one way of achieving this response is through TLR9
stimulation via CpG.
Another functionofIL-10istopromoteBcellgrowth,
differentiation and antibody class switching [56–58]; so
its production by B cells could have an autocrine effect
[59]. IL-10secretion from Bcells has been demonstrated
in human B cell lymphomas [59]. Thus, in response to
TLR and T-dependent activation signals, B cell-derived
IL-10 may act to promote the ensuing response by
expanding the B cell population and inducing class
switching to appropriate isotypes.
Although IFN-csecretionbyBcellshasbeen reported
previously [60], our demonstration that this cytokine
can be secreted by B cells in response to defined TLR
combinations is an exciting and novel finding. We found
that combined stimulation through TLR2, 4 and 9 with
TLR ligands (PAM3CSK4 or PGN, LPS and CpG) induced
IFN-c secretion by B cells, which was not apparent when
anyof thesestimuliwereusedalone,inconjunctionwith
BCR signalling or with costimulation through CD40.
This is an important consideration when assessing the
physiological importance of in vitro TLR stimulations.
The situation in vivo during a bacterial infection would
certainly provide a range of TLR signals to the B cell. For
instance, B cells from Salmonella-infected mice make
very significant amounts of IFN-c when restimulated
with bacterial antigens (Mastroeni, Barr and Gray,
unpublished). This B cell-derived IFN-c may act on
T cells or even, in an autocrine fashion, on B cells
themselves. Thus, it may regulate homing of immature
B cells [61] and has been shown to be important during
Borrelia burgdorferi infection [62]. As APC,
IFN-c-secreting B cells could influence Th1 differentia-
tion and, in addition, initiate isotype switching (to
IgG2a/c and IgG3). Autocrine IFN-c may be particularly
important as a switch factor for IgG3 in response to
T-independent antigens [63]. Interestingly, a recent
report by Ehlers et al. [13] demonstrated defective class
switching to IgG2a in MyD88-deficient animals,
although the possibility that this was an autocrine
B cell effect was not investigated.
Most important of all, our results show that there are
distinct response patterns from different APC popula-
tions stimulated via the same TLR. Thus, B cells make
IL-10 and IL-6 following TLR4 and 9 ligation, in contrast
toDC that makeIL-12, IL-6 and IL-10.In addition, IL-6 is
elicited in B cells via TLR2, 4 and 9, but by TLR3, 4 and 9
in DC. This suggests that the composition of the
membrane-proximal TLR signalling elements (adaptors)
differs between these two important APC populations.
The reasons for this differential APC response are surely
bound up in the different in vivo APC function of DC and
B cells. We would suggest that soon after the first wave
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underway, both the TLR-mediated and adaptive activa-
tion of B cells gives rise to cells that are capable of
modulating the dominant T cells response, either to
down-regulate the response in general, to prevent
strongly polarised responses [23–25] or in some cases
(IFN-c) to reinforce particularly important responses.
Materials and methods
Mice
Mice were bred and maintained in specific pathogen-free
conditions at the School of Biological Sciences Animal Facility
at the University of Edinburgh. All experiments utilised non-
immunised female C57BL/6 mice at 6–10 wk of age. Experi-
ments were covered by a Project Licence granted by the Home
Office under the Animal (Scientific Procedures) Act 1986. This
licence was approved locally by the University of Edinburgh
Ethical Review Committee.
Preparation and sorting of highly purified B cells
Splenic B cells were isolated from naive female C57BL/6 mice
usingstandardmagneticsortingtechniques.Followingmanual
disruption in complete medium [Iscove's modied Dulbecco's
medium (IMDM) + 5% FCS and penicillin/streptomycin] and
lysis of red blood cells, splenocytes were labelled with anti-
CD19 microbeads, washed and sorted over two consecutive LS
columns in accordance with the manufacturer's instructions
(Miltenyi Biotech, Bisley, UK). Passing cells over a second
column led to purities in excess of 99% CD19
+ve cells (data not
shown). These highly purified B cells were analysed by FACS
for contaminating T cells and DC using anti-CD3 and anti-
CD11c antibodies. B cells were further purified by flow
cytometric sorting carried out following the CD19 enrichment
described above. FO B cells were defined as CD19
+ve, CD21
high
and CD23
high. MZ B cells were defined as CD19
+ve, CD21
high
and CD23
med/low (see Fig. 1A). B1 cells were defined as
CD19
+ve, B220
int and CD5
int, whereas B2 cells were defined as
CD19
+ve, B220
high and CD5
–ve (see Fig. 1B). FO, MZ and B2
subset sorts were routinely >94% pure. B1 cell sorts were
routinely >85% pure.
Preparation of BMDC
BMDC were prepared using a modified version of the protocol
originally described by Inaba et al. [64]. Briefly, marrow was
harvested from the femurs and tibias of female C57BL/6 mice.
Following red blood cell lysis, cells were seeded at
3.75   10
5 cells/mL in RPMI 1640 supplemented with 10%
FCS and 5% supernatant from GM-CSF transfected X-63 cells
[22]. After 3 days, the incubation medium was aspirated and
fresh GM-CSF-supplemented medium added. This washing
process was repeated again at day 6. Cells were harvested at
day 7, giving approximately 90% pure CD11c
+ve and MHC
class II
+vecells. These cells werethen labelledwith anti-CD11c
microbeads and positively sorted using standard MACS
protocols. This regime yielded greater than 97% pure BMDC
(data not shown).
Nucleic acid extraction and PCR analyses
mRNA was extracted from cells using the Micro-FastTrack 2.0
mRNA extraction kit (Invitrogen, Renfrew, UK) in accordance
with the manufacturer's instructions. Contaminating DNA was
removed from samples by DNase treatment with Ambion's
DNA-Free (Ambion Europe, Dublin, Ireland) prior to second-
strand synthesis. cDNA was generated from mRNA by reverse
transcription using the StrataScript second-strand synthesis kit
(Stratagene, UK). Semi-quantitativeRT- and QRT-PCR analysis
was carried out using a range of primers, the sequences,
melting temperatures and product sizes of which are given in
Table 2. Where possible, primers were designed to span exon
junctions to further reduce the possibility of amplification of
non-specific products from contaminating genomic DNA. PCR
products were visualised on ethidium bromide-labelled 1.8%
agarose gels using standard techniques. QRT-PCR was
performed using Roche SYBR green and the LightCycler
thermal cycler (Roche Diagnostics, Lewes, UK). Products were
quantified by comparing expression levels of the gene of
interest relative to the expression levels of the housekeeping
control gene b-actin.
QRT-PCR array analysis
An RT
2 Profiler PCR array system was used to quantify gene
expression using a TLR signalling-focused array in compliance
with the manufacturer's instructions (SuperArray Bioscience
Corporation, Frederick, MD). Briefly, after 24 h of stimulation
of CD19
+ve B cells or BMDC with LPS at 1 lg/mL, total RNA
was extracted from 2   10
6 cells using the Qiagen RNeasy
minikit and DNase (Qiagen, Crawley, UK) treated. Reverse
transcription was carried out using the RT
2 PCR array first-
strand kit (SuperArray). Quality control of all samples was
carried out on a SuperArray QC array. PCR were performed
using the Chromo4 real-time PCR system, and data were
analysed by the DDCt method using data analysis templates
from SuperArray.
In vitro TLR stimulation assays
Highly purified CD19
+ve B cells, CD11c
+ve BMDC and B cell
subsets were cultured at 2   10
6 cells/mL in complete
medium under a range of conditions used to mimic various
modes of B cell activation. T-dependent activation was
mimicked by simultaneous stimulation through the BCR and
CD40 using agonistic antibodies against the Ig kappa light
chain (clone 187.1) and anti-CD40 antibody (clone FGK-45),
which were produced in-house by standard mAb purification
techniques on hybridoma supernatants. These mAb were used
at 15 and 10 lg/mL, respectively. Endotoxin-free TLR ligands
were purchased from InVivogen (Autogen Bioclear UK Ltd.)
and added to cultures, either alone or in the presence of anti-
CD40 antibody, at concentrations detailed below. TLR2
agonists zymosan, PGN and PAM3CSK4 were used at 10, 10
and 0.2 lg/mL, respectively; poly I:C (TLR3 ligand) was used
at25 lg/mL;LPS(TLR4ligand)fromE. coli0:111B4wasused
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Gene Primer Sequence Amplicon size (bp) Tm
b-Actin B-act FOR TGG AAT CCT GTG GCA TCC ATG AAA C 348 58.0
B-act REV TAA AAC GCA GCT CAG TAA CAG TCC G 58.0
GAPDH GAP FOR TTC ACC ACC ATG GAG AAG GC 236 59.4
GAP REV GGC ATG GAC TGT GGT CAT GA 59.4
CD3n CD3e FOR CCT TTT CTC CTC ATC CTC CC 250 54.0
CD3e REV TGC ACT CCT GCT GAA TTT TG 50.0
IL-6 IL6 FOR CCT CTC TGC AAG AGA CTT CCA TC 520 68.3
IL6 REV AGC CAC TCC TTC TGT GAC TCC AG 70.9
IL-10 IL10 FOR GGT TGC CAA GCC TTA TCG GA 190 59.4
IL10 REV ACC TGC TCC ACT GCC TTG CT 61.4
IL-12p40 IL12 FOR GGA AGC ACG GCA GCA GAA TA 180 59.4
IL12 REV AAC TTG AGG GAG AAG TAG GAA TGG 61.0
IFNg IFNg FOR AGC GCT GAC TGA ACT CAG ATT GTA G 243 58.0
IFNg REV GTC ACA GTT TTC AGC TGT ATA GGG 56.0
TLR1 TLR1 FOR GGA TGT GTC CGT CAG CAC TA 340 59.4
TLR1 REV TGT AAC TTT GGG GGA AGC TG 57.3
QRTTLR1-1 TAC AGT TCC TGG GGTTGAGC 216 54.0
QRTTLR1-2 TAG TGC TGA CGG ACA CAT CC 54.0
TLR2 TLR2 FOR CAG ACG TAG TGA GCG AGC TG 390 61.4
TLR2 REV GGC ATC GGA TGA AAA GTG TT 55.3
QRTTLR2-1 CGT TGT TCC CTG TGT TGC T 119 51.0
QRTTLR2-2 AAA GTG GTT GTC GCC TGC T 51.0
TLR3 TLR3 FOR GAG GGC TGG AGG ATC TCT TT 353 59.4
TLR3 REV TGC CTC AAT AGC TTG CTG AA 55.3
QRTTLR3-1 TTG CGT TGC GAA GTG AAG 406 48.0
QRTTLR3-2 TAA AAA GAG CGA GGG GAC AG 52.0
TLR4 TLR4 FOR GCT TTC ACC TCT GCC TTC AC 361 59.4
TLR4 REV CGA GGC TTT TCC ATC CAA TA 55.3
QRTTLR4-1 TTC ACC TCT GCC TTC ACT ACA 225 52.0
QRTTLR4-2 GGG ACTT CTC AAC CTT CTC AA 52.0
TLR5 TLR5 FOR GCT TTG TTT TCT TCG CTT CG 342 55.3
TLR5 REV ACA CCA GCT TCT GGA TGG TC 59.4
QRTTLR5-1 CAG GAT GTT GGC TGG TTT CT 169 52.0
QRTTLR5-2 CGG ATA AAG CGT GGA GAG TT 52.0
TLR6 TLR6 FOR GCA ACA TGA GCC AAG ACA GA 349 57.3
TLR6 REV GTT TTG CAA CCG ATT GTG TG 55.3
QRTTLR6-1 ATG GCA CAG CGG ACT TAC TT 170 52.0
QRTTLR6-2 ATG AGA GCC CAG GTT GAC AG 54.0
TLR7 TLR7 FOR ATT CAG AGG CTC CTG GAT GA 264 57.3
TLR7 REV AGG GAT GTC CTA GGT GGT GA 59.4
QRTTLR7-1 GCT GTG TGG TTT GTC TGG TG 270 54.0
QRTTLR7-2 CCC CTT TAT CTT TGC TTT CC 50.0
TLR8 TLR8 FOR TCC TGG GGA TCA AAA ATC AA 302 53.2
TLR8 REV AAG GTG GTA GCG CAG TTC AT 57.3
QRTTLR8-1 GAC TTC ATC CAC ATC CCA AA 156 50.0
QRTTLR8-2 TCC CAA TCC CTC TCC TCT AA 52.0
TLR9 TLR9 FOR ACC CTG GTG TGG AAC ATC AT 341 57.3
TLR9 REV GTT GGA CAG GTG GAC GAA GT 59.4
QRTTLR9-1 GAA AGC ATC AAC CAC ACC AA 304 50.0
QRTTLR1-2 ACA AGT CCA CAA AGC GAA GG 52.0
a) Nucleotide sequences for each of the RT-PCR and QRT-PCR products (excluding those in the signalling array analysis) are listed,
including indications of PCR product size and theoretical melting temperature (Tm).
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loxoribine (TLR7) was used at 100 lM, and the TLR9 ligand
CpG (ODN 1826) and its non-CpG-containing oligonucleotide
control were used at 25 lg/mL. CpG and non-CpG sequences
were as follows: ODN 1826 50-TCC ATG ACG TTC CTG ACG
TT-30 and ODN 1826 control 50-TCC ATG AGC TTC CTG AGC
TT-30. PMA and ionomycin (Sigma, UK) were used at 50 ng/
mL and 1 lg/mL, respectively. Cells were cultured under these
conditions for 1–5 days. After 1 day, an aliquot of cells was
removed for FACS analysis of activation markers. At days 1, 3
and 5,aliquots ofsupernatant were removed forELISA assayof
cytokine concentrations.
Cytokine ELISA
Supernatants from TLR-stimulated cultures were assayed to
determine cytokine concentrations by standard capture ELISA
techniques using commercially available paired antibody sets
for IL-6, IL-10, IL-12p40 and IFN-c (BD Pharmingen, San
Diego, CA). Briefly, Nunc Maxisorp plates (Fisher Scientific,
Loughborough, UK) were coated overnight at 4
 C with capture
mAb at 5 lg/mL in PBS. Plates were then blocked for 1 h at
room temperature with 3% BSA. Supernatants were then
added to the plate and left for 2 h at room temperature.
Following washing, biotinylated capture mAb was applied and
the plates incubated for a further hour at room temperature.
Streptavidin-alkaline phosphatase was then added and,
following incubation at room temperature and washing,
p-NPP substrate was added. Plates were read at 405 nm once
the substrate had developed, and cytokine concentration was
determined by extrapolation from the standard curve.
Flow cytometric analysis
Following overnight incubation with the various TLR agonists,
B cells were assayed for the expression of various activation
markers. The antibodies used, all obtained from BD Pharmin-
gen, were as follows; anti-CD23-PE, anti-CD25-APC, anti-
CD80-PE, anti-CD86-PE, anti-MHC class II-FITC, and anti-
CD40-biotin. With each of the relevant mAb in FACS buffer
(PBS + 1% BSA + 0.05% NaN3), 5   10
5 cells were incubated
for 20 min on ice. Cells were then washed three times and
analysed on a FACSCalibur flow cytometer (BD Pharmingen).
Data were analysed using FlowJo software (Tree Star Inc.).
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